by Marisa Wexler, MS | Mar 6, 2026 | Myeloma News
The experimental therapy 177Lu-edotreotide outperformed the approved treatment everolimus in prolonging progression-free survival in people with pancreatic neuroendocrine tumors (PNETs), according to a new analysis of a Phase 3 clinical trial. ITM Isotope Technologies...
by MM360 Staff | Mar 6, 2026 | Myeloma News
Source: Pharmacy Times articles Post Content Read More
by Marisa Wexler, MS | Mar 5, 2026 | Myeloma News
A committee of the European Medicines Agency (EMA) has recommended the approval of Ipsen‘s tovorafenib for the treatment of pediatric low-grade glioma (pLGG). If authorized by the European Commission, the therapy would become a new targeted option for children 6...
by Marisa Wexler, MS | Mar 4, 2026 | Myeloma News
A low dose of alnodesertib added to standard chemotherapy significantly reduced the likelihood of disease progression among people with platinum-resistant high-grade serous ovarian carcinoma (HGSOC) in an early clinical trial. Findings from the Phase 2a study...
by MM360 Staff | Mar 4, 2026 | Uncategorized
Source: CURE articles Post Content Read More
